Volume 28, Issue 7, July 2023

This narrative review summarizes advances in the treatment of cancer-associated venous thromboembolism, outlines key unmet needs with the current treatment, and discusses how factor XI inhibitors may address the current knowledge gaps.

This article reviews available data that could help guide treatment decisions for germline BRCA1/2 mutation carriers with high-risk, early-stage breast cancer.

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy. This study aimed to identify patient characteristics associated with CIPN severity during weekly paclitaxel chemotherapy in people with early-stage breast cancer.

Hyperglycemia is a common adverse event for patients receiving alpelisib. This article reports the frequency of alpelisib-associated hyperglycemia in a real-world setting and evaluates proposed risk factors.

Alpelisib combined with fulvestrant is used to treat patients with HR+/HER2–/PIK3CA-mutated metastatic breast cancer. Adverse drug reactions with alpelisib are common, including hyperglycemia and rash. This article describes extraordinary and life-threatening reactions beyond skin rash in two patients with progressive PIK3CA-mutated metastatic cancer.

More effective therapeutic strategies targeting underlying genomic drivers, as well as novel combinations, are urgently needed for treatment of triple-negative breast cancer (TNBC). This article evaluates the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic TNBC.

Assessing gender and race representation in leadership editorial board positions in major journals is critical in furthering equity. This article examines the gender and race/ethnicity representation in editorial board positions at leading hematology and oncology journals.

Carcinoid heart disease (CaHD) is a complication for patients with metastatic neuroendocrine tumors and carcinoid syndrome. This article reviews major CaHD guidance papers and provides expert clinical perspectives on how to implement these recommendations into clinical practice, with the goal of increasing screening for CaHD, optimizing multidisciplinary collaboration, and discussing exploratory therapies to prevent the development of CaHD.

The Pancreatic Cancer Action Network (PanCAN) position statements can provide supplementary guidance to healthcare professionals for the management of pancreatic cancer. This review summarizes the rationale and sources for these position statements related to diagnosis, treatment, and care and provides information about resources to make these recommendations accessible for patients and their medical teams.

This review evaluates the pooled data from phase III trials of androgen-receptor signaling inhibitors in patients with metastatic castration-sensitive prostate cancer to dissect the impact of abiraterone acetate plus prednisone versus non-steroidal anti-androgens on overall survival for metastatic castration-sensitive prostate cancer with visceral metastasis.

In this study, comprehensive genomic profiling (CGP) was used to evaluate the frequency of NF2 genomic alterations in histologic subtypes of kidney tumors and co-occurring genomic alterations in other genes and biomarkers.

Because of possible treatment with TRK inhibitors for advanced tumors, it is important to determine the incidence and molecular characteristics of NTRK gene fusions in patients with bilio-pancreatic cancers. The aim of the present study was to apply the guidelines for NTRK testing algorithm to a series of patients with bilio-pancreatic cancers.

Immune checkpoint inhibitors (ICIs) are effective for advanced hepatocellular carcinoma (HCC), but the correlation between the clinical efficacy of ICIs and the development of immune-related adverse events (irAEs) in patients with HCC is unclear. This article reports on the association between irAE development and survival in patients with HCC treated with atezolizumab plus bevacizumab.

This article evaluates the anti-tumor activity and toxicity profile of the combination of MEDI0457 and durvalumab for patients with recurrent or metastatic HPV-associated anogenital cancers.

This case report describes a patient with a history of 2 primary cancers who harbored a likely pathogenic TP53 variant with low variant allele frequency in a blood sample. Such a result could have been misinterpreted as a Li-Fraumeni case, but other tests were conducted to elucidate the case.

This case report is the first to describe the treatment of invasive lobular breast cancer carrying HER2 mutations with combined treatment involving the tyrosine kinase inhibitor pyrotinib and the antibody-drug conjugate ado-trastuzumab emtansine. The regimen was promising.

This article summarizes the scientific review of the application that led to the positive opinion of asciminib by the European Medicines Agency's Committee for Medicinal Products for Human Use.

It is important to understand how to effectively communicate with consumers about drug efficacy. This article reports the results from two experimental studies that addressed the communication of overall survival, overall response rate, and progression-free survival in direct-to-consumer prescription drug ads.

In patients with soft-tissue sarcoma re-excised after unplanned tumor resection, recommandations of adjuvant treatment remain unclear. This article reports the efficacy and safety of adjuvant radiotherapy in this indication..

This article reports the results of a clinical trial of oral LCL161 administered in combination with oral topotecan in patients with relapsed/refractory small cell lung cancer and select gynecological cancers.

For patients with non-metastatic castration resistant prostate cancer, this clinical trial compared the androgen receptor antagonist flutamide with or without PROSTVAC.

This phase II trial evaluated the safety and activity of the MEK inhibitor binimetinib combined with hydroxychloroquine in patients with advanced KRAS-mutant non-small cell lung cancer.

This article presents a survival analysis of the phase II OGSG1602 trial on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer.

This article evaluates the toxicity and feasibility of gemcitabine/nab-paclitaxel/S-1 chemotherapy on a 21-day cycle in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma, reporting dose-limiting toxicity and maximum tolerated dose of S-1 in this regimen.

This brief communication examines differences in attitudes and participation in the medical aid in dying (MAiD) process between oncologists and non-oncologists, using data from a recent survey of physicians regarding MAiD.

This letter to the editor expresses concerns related to immortal time bias that may partially account for recently published study results.

This letter to the editor responds to the letter from Su et al, regarding concerns related to immortal time bias that may partially account for recently published study results.